vs
Side-by-side financial comparison of Beneficient (BENF) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Beneficient is the larger business by last-quarter revenue ($18.7M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). Beneficient runs the higher net margin — 106.7% vs -0.8%, a 107.5% gap on every dollar of revenue. On growth, Beneficient posted the faster year-over-year revenue change (322.5% vs -25.7%).
Beneficient is a financial services firm specializing in alternative asset liquidity solutions. It offers tailored options for holders of illiquid alternative investments including private equity, hedge fund stakes, and real assets, serving institutional investors, high-net-worth individuals, and family offices primarily in North America.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BENF vs CTMX — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.7M |
| Net Profit | $19.9M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 21.1% | -6.9% |
| Net Margin | 106.7% | -0.8% |
| Revenue YoY | 322.5% | -25.7% |
| Net Profit YoY | 330.5% | 97.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.7M | — | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-12.6M | $18.7M | ||
| Q1 25 | $-31.0M | $50.9M | ||
| Q4 24 | $4.4M | $38.1M | ||
| Q3 24 | $8.6M | $33.4M | ||
| Q2 24 | $10.0M | $25.1M | ||
| Q1 24 | — | $41.5M |
| Q4 25 | $19.9M | — | ||
| Q3 25 | $-17.9M | — | ||
| Q2 25 | $-92.6M | $-154.0K | ||
| Q1 25 | $-44.6M | $23.5M | ||
| Q4 24 | $-8.6M | $18.9M | ||
| Q3 24 | $9.7M | $5.7M | ||
| Q2 24 | $44.3M | $-6.5M | ||
| Q1 24 | — | $13.8M |
| Q4 25 | 21.1% | — | ||
| Q3 25 | 646.5% | — | ||
| Q2 25 | 734.0% | -6.9% | ||
| Q1 25 | 146.3% | 44.4% | ||
| Q4 24 | -215.3% | 46.4% | ||
| Q3 24 | -160.2% | 12.3% | ||
| Q2 24 | — | -33.7% | ||
| Q1 24 | — | 28.1% |
| Q4 25 | 106.7% | — | ||
| Q3 25 | 648.1% | — | ||
| Q2 25 | 734.0% | -0.8% | ||
| Q1 25 | 144.1% | 46.2% | ||
| Q4 24 | -195.5% | 49.6% | ||
| Q3 24 | 113.9% | 17.2% | ||
| Q2 24 | 441.1% | -26.0% | ||
| Q1 24 | — | 33.3% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-128.6M | $119.9M |
| Total Assets | $337.9M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $7.6M | $49.0M | ||
| Q1 25 | $1.3M | $47.6M | ||
| Q4 24 | $4.1M | $38.1M | ||
| Q3 24 | $4.5M | $40.6M | ||
| Q2 24 | $4.4M | $43.2M | ||
| Q1 24 | — | $36.2M |
| Q4 25 | $-128.6M | — | ||
| Q3 25 | $-142.8M | — | ||
| Q2 25 | $-120.4M | $119.9M | ||
| Q1 25 | $-34.9M | $25.0M | ||
| Q4 24 | $14.3M | $-456.0K | ||
| Q3 24 | $-13.2M | $-23.5M | ||
| Q2 24 | $-148.3M | $-31.2M | ||
| Q1 24 | — | $-31.7M |
| Q4 25 | $337.9M | — | ||
| Q3 25 | $316.2M | — | ||
| Q2 25 | $334.5M | $175.1M | ||
| Q1 25 | $354.9M | $98.5M | ||
| Q4 24 | $400.0M | $120.5M | ||
| Q3 24 | $368.8M | $139.0M | ||
| Q2 24 | $361.3M | $159.2M | ||
| Q1 24 | — | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.4M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -0.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.4M | — | ||
| Q3 25 | $-14.5M | — | ||
| Q2 25 | $-10.8M | $-15.8M | ||
| Q1 25 | $-37.7M | $-21.0M | ||
| Q4 24 | $-10.0M | $-19.9M | ||
| Q3 24 | $-8.6M | $-20.7M | ||
| Q2 24 | $-10.6M | $-19.5M | ||
| Q1 24 | — | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-10.9M | $-15.8M | ||
| Q1 25 | $-38.8M | $-21.2M | ||
| Q4 24 | $-10.0M | $-20.0M | ||
| Q3 24 | $-8.9M | $-20.7M | ||
| Q2 24 | $-11.3M | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 86.6% | -84.6% | ||
| Q1 25 | 125.3% | -41.6% | ||
| Q4 24 | -227.2% | -52.5% | ||
| Q3 24 | -103.7% | -62.1% | ||
| Q2 24 | -112.6% | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -0.8% | 0.1% | ||
| Q1 25 | -3.5% | 0.2% | ||
| Q4 24 | 1.0% | 0.2% | ||
| Q3 24 | 3.1% | 0.1% | ||
| Q2 24 | 6.6% | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | -0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | -0.88× | -3.61× | ||
| Q2 24 | -0.24× | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BENF
| Ben Liquidity | $8.2M | 44% |
| Other | $7.6M | 41% |
| Ben Custody | $2.9M | 16% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
